Raymond M. Jordt - Jan 1, 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: Chief Business Officer
Signature: /s/ Richard I. Eisenstadt as Attorney-in-Fact
Stock symbol: ALT
Transactions as of: Jan 1, 2024
Transactions value $: -$28,159
Form type: 4
Date filed: 1/4/2024, 06:00 PM
Previous filing: Aug 2, 2023
Next filing: Jan 29, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Options Exercise	$0	+9.38K	+511.74%	$0.00	11.2K	Jan 1, 2024	Direct	F1
transaction	ALT	Common Stock, par value $0.0001	Tax liability	-$28.2K	-2.5K	-22.33%	$11.25	8.7K	Jan 1, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Restricted Stock Units	Options Exercise	$0	-9.38K	-25%	$0.00	28.1K	Jan 1, 2024	Common Stock, par value $0.0001	9.38K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2	Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3	The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.